These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 10435395)

  • 21. Prefrontal cortex 5-HT2 receptors in depression: an [18F]setoperone PET imaging study.
    Meyer JH; Kapur S; Houle S; DaSilva J; Owczarek B; Brown GM; Wilson AA; Kennedy SH
    Am J Psychiatry; 1999 Jul; 156(7):1029-34. PubMed ID: 10401447
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The serotonergic antidepressant nefazodone inhibits the serotonin transporter: in vivo and ex vivo studies.
    Owens MJ; Ieni JR; Knight DL; Winders K; Nemeroff CB
    Life Sci; 1995; 57(24):PL373-80. PubMed ID: 7475971
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients.
    Nyberg S; Eriksson B; Oxenstierna G; Halldin C; Farde L
    Am J Psychiatry; 1999 Jun; 156(6):869-75. PubMed ID: 10360125
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The antidepressant, nefazodone, attenuates corticosterone-induced increases in 5-HT2A receptor-mediated behaviors in the female rat.
    Hanson LA; Gorzalka BB; Brotto LA
    Eur J Pharmacol; 1998 Jan; 342(2-3):163-5. PubMed ID: 9548381
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nefazodone attenuates the stress-induced facilitation of wet dog shaking behaviour but not the facilitation of sexual behaviour in female rats.
    Brotto LA; Hanson LA; Gorzalka BB
    Eur J Pharmacol; 1999 Sep; 381(2-3):101-4. PubMed ID: 10554876
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Estimation of neocortical serotonin-2 receptor binding potential by single-dose fluorine-18-setoperone kinetic PET data analysis.
    Petit-Taboué MC; Landeau B; Osmont A; Tillet I; Barré L; Baron JC
    J Nucl Med; 1996 Jan; 37(1):95-104. PubMed ID: 8544011
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PET imaging of serotonin type 2A receptors in late-life neuropsychiatric disorders.
    Meltzer CC; Price JC; Mathis CA; Greer PJ; Cantwell MN; Houck PR; Mulsant BH; Ben-Eliezer D; Lopresti B; DeKosky ST; Reynolds CF
    Am J Psychiatry; 1999 Dec; 156(12):1871-8. PubMed ID: 10588399
    [TBL] [Abstract][Full Text] [Related]  

  • 28. LY367265, an inhibitor of the 5-hydroxytryptamine transporter and 5-hydroxytryptamine(2A) receptor antagonist: a comparison with the antidepressant, nefazodone.
    Pullar IA; Carney SL; Colvin EM; Lucaites VL; Nelson DL; Wedley S
    Eur J Pharmacol; 2000 Oct; 407(1-2):39-46. PubMed ID: 11050288
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Parametric PET imaging of 5HT2A receptor distribution with 18F-setoperone in the normal human neocortex.
    Petit-Taboué MC; Landeau B; Barré L; Onfroy MC; Noël MH; Baron JC
    J Nucl Med; 1999 Jan; 40(1):25-32. PubMed ID: 9935052
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A positron emission tomography study of the effects of treatment with valproate on brain 5-HT2A receptors in acute mania.
    Yatham LN; Liddle PF; Lam RW; Adam MJ; Solomons K; Chinnapalli M; Ruth TJ
    Bipolar Disord; 2005; 7 Suppl 5():53-7. PubMed ID: 16225561
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Opposite effects of nefazodone in two human models of anxiety.
    Silva M; Hetem LA; Guimarães FS; Graeff FG
    Psychopharmacology (Berl); 2001 Aug; 156(4):454-60. PubMed ID: 11498723
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Test-retest variability of high resolution positron emission tomography (PET) imaging of cortical serotonin (5HT2A) receptors in older, healthy adults.
    Chow TW; Mamo DC; Uchida H; Graff-Guerrero A; Houle S; Smith GS; Pollock BG; Mulsant BH
    BMC Med Imaging; 2009 Jul; 9():12. PubMed ID: 19580676
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Loss of brain 5-HT2 receptors in Alzheimer's disease. In vivo assessment with positron emission tomography and [18F]setoperone.
    Blin J; Baron JC; Dubois B; Crouzel C; Fiorelli M; Attar-Lévy D; Pillon B; Fournier D; Vidailhet M; Agid Y
    Brain; 1993 Jun; 116 ( Pt 3)():497-510. PubMed ID: 8513389
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PET imaging of central 5-HT2A receptors with carbon-11-MDL 100,907.
    Ito H; Nyberg S; Halldin C; Lundkvist C; Farde L
    J Nucl Med; 1998 Jan; 39(1):208-14. PubMed ID: 9443763
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Attenuation of the prolactin-stimulating and hyperthermic effects of nefazodone after subacute treatment.
    Walsh AE; Cowen PJ
    J Clin Psychopharmacol; 1994 Aug; 14(4):268-73. PubMed ID: 7962683
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reproducibility of in vivo brain measures of 5-HT2A receptors with PET and.
    Soares JC; van Dyck CH; Tan P; Zoghbi SS; Garg P; Soufer R; Baldwin RM; Fujita M; Staley JK; Fu X; Amici L; Seibyl J; Innis RB
    Psychiatry Res; 2001 Apr; 106(2):81-93. PubMed ID: 11306248
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nefazodone. A review of its pharmacology and clinical efficacy in the management of major depression.
    Davis R; Whittington R; Bryson HM
    Drugs; 1997 Apr; 53(4):608-36. PubMed ID: 9098663
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Paradoxical effects of lithium on serotonergic receptor function: an immunocytochemical, behavioural and autoradiographic study.
    Moorman JM; Leslie RA
    Neuropharmacology; 1998; 37(3):357-74. PubMed ID: 9681934
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nefazodone: preclinical pharmacology of a new antidepressant.
    Eison AS; Eison MS; Torrente JR; Wright RN; Yocca FD
    Psychopharmacol Bull; 1990; 26(3):311-5. PubMed ID: 2274630
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Brain 5-HT2A receptor occupancy of deramciclane in humans after a single oral administration--a positron emission tomography study.
    Kanerva H; Vilkman H; Någren K; Kilkku O; Kuoppamäki M; Syvälahti E; Hietala J
    Psychopharmacology (Berl); 1999 Jul; 145(1):76-81. PubMed ID: 10445375
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.